Vitridinol, 400 mg 56 pcs.

Pharmacotherapeutic group: Intestinal antiseptic and astringent < br> < br> ATX code: A02BX05 < br> < br> Pharmacodynamics:< br> < br> Antiulcer agent with bactericidal activity against Helicobacter pylori. It also has anti-inflammatory and astringent activity. In the acidic environment of the stomach, insoluble bismuth oxychloride and citrate precipitate to form chelated compounds with a protein substrate in the form of a protective film on the surface of ulcers and erosions. By increasing the synthesis of prostaglandin E formation of mucus and secretion of hydrocarbonate stimulates the activity of cytoprotective mechanisms increases resistance of the mucous membrane of the gastrointestinal tract to the effects of pepsin hydrochloric acid enzymes and bile acid salts. Leads to the accumulation of epidermal growth factor in the defect area. Reduces pepsin and pepsinogen activity.< br> < br> < br> Pharmacokinetics:< br> < br> Bismuth tricalium dicitrate is practically not absorbed from the gastrointestinal tract. It is excreted mainly with the feces. A small amount of bismuth entered the plasma is excreted by the kidneys.

Indications

Peptic ulcer of the stomach and duodenum in the acute phase, incl. associated with Helicobacter pylori.

Chronic gastritis and gastrodoudenitis in the acute phase (including those associated with Helicobacter pylori).

Functional dyspepsia not associated with organic gastrointestinal diseases.

Irritable bowel syndrome occurs predominantly with symptoms of diarrhea.

Pharmacological effect

Pharmacotherapeutic group: Antiseptic intestinal and astringent

ATX code: A02BX05

Pharmacodynamics:

Antiulcer agent with bactericidal activity against Helicobacter pylori. It also has anti-inflammatory and astringent effects. In the acidic environment of the stomach, insoluble bismuth oxychloride and citrate are deposited and chelate compounds are formed with the protein substrate in the form of a protective film on the surface of ulcers and erosions. By increasing the synthesis of prostaglandin E, the formation of mucus and the secretion of bicarbonate stimulates the activity of cytoprotective mechanisms and increases the resistance of the gastrointestinal mucosa to the effects of pepsin, hydrochloric acid, enzymes and bile salts. Leads to the accumulation of epidermal growth factor in the defect area. Reduces the activity of pepsin and pepsinogen.

Pharmacokinetics:

Bismuth tripotassium dicitrate is practically not absorbed from the gastrointestinal tract. It is excreted mainly in feces. A small amount of bismuth entering the plasma is excreted from the body by the kidneys.

Special instructions

The drug should not be used for more than 8 weeks.

During treatment, it is not recommended to exceed the established daily doses for adults and children.
During treatment with Vitridinol, you should not use other drugs containing bismuth because the risk of systemic side effects increases due to an increase in the concentration of bismuth in the blood.

When using Vitridinol, stool may turn dark due to the formation of bismuth sulfide. Sometimes there is a slight darkening of the tongue.

Impact on the ability to drive vehicles. Wed and fur.:

There are no data on the effect of the drug Vitridinol on the ability to drive a car and operate machinery.

Active ingredient

Bismuth tripotassium dicitrate

Composition

Active substance:

bismuth tripotassium dicitrate – 304.6 mg, in terms of bismuth oxide Bi2O3 – 120 mg.

Excipients:

corn starch – 70.6 mg,

povidone K30 – 17.7 mg,

potassium polyacrylate – 23.6 mg,

macrogol 6000 – 6.0 mg,

magnesium stearate – 2.0 mg.

Shell: Opadry 11 85F38077 – 4.3 mg, consists of polyvinyl alcohol, polyethylene glycol/macrogol 3350, quinoline yellow (E 104), talc, titanium dioxide, indigo carmine (E 132).

Pregnancy

Contraindicated during pregnancy. Stop breastfeeding during treatment.

Contraindications

Increased individual sensitivity to the components of the drug; pregnancy;

breastfeeding period;

taking medications containing bismuth;

severe renal impairment (severe renal failure (creatinine clearance less than 30 ml/min) and chronic renal failure);

children under 4 years of age.

Side Effects

The following adverse events noted with the use of bismuth tripotassium dicitrate are distributed according to the frequency of occurrence in accordance with the following gradation: very often (≥ 1/10); often (≥ 1/100, < 1/10); uncommon (≥ 1/1000, < 1/100); rare (≥ 1/10000, < 1/1000); very rare (<1/10000).

From the gastrointestinal tract: very often – black stool; uncommon – nausea, vomiting, diarrhea or constipation.

Allergic reactions: infrequently – skin rash, itching; very rarely – anaphylactic reactions.

From the nervous system: very rarely – with long-term use in high doses – encephalopathy associated with the accumulation of bismuth in the central nervous system.

Side effects are reversible and disappear quickly after discontinuation of the drug. If any of the side effects indicated in the instructions get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

For half an hour before and after taking the drug, it is not recommended to take other medications internally, as well as take food and liquids, in particular antacids, milk, fruits and fruit juices.

This is due to the fact that when taken orally simultaneously, they can affect the effectiveness of the drug. Combined use of the drug with tetracyclines reduces the absorption of the latter.

During treatment with the drug you should not drink alcohol.

Overdose

Long-term use of the drug in doses exceeding the recommended ones can cause bismuth poisoning. Symptoms of poisoning: dyspepsia, rash, inflammation of the oral mucosa, characteristic darkening in the form of blue lines on the gums; Possible renal dysfunction. These symptoms are completely reversible when the drug is discontinued.

Treatment: there is no specific antidote. In case of an overdose of the drug, gastric lavage, intake of enterosorbents and symptomatic therapy aimed at maintaining kidney function are indicated. In case of overdose, the administration of saline laxatives is also indicated.

Further treatment should be symptomatic. In case of impaired renal function, accompanied by a high level of bismuth in the blood plasma, complexing agents – dimercaptosuccinic and dimercaptopropanesulfonic acids – can be administered. With the development of severe renal dysfunction, hemodialysis is indicated.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 ° C.

Keep out of the reach of children.

Shelf life

3 years. Do not use after the expiration date indicated on the package.

Manufacturer

Velfarm LLC, Russia